Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral treprostinil sustained-release tablets versus placebo in pulmonary arterial hypertension
NL-OMON35674Phase 3Active, not recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing UT-15C SR tablets with Placebo (2 arms). Primary endpoint: Change in 6-minute walk distance from baseline to Week 16. Started Apr 2010; status: active, not recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON35674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35674.